Cargando…
Experiences of Patients With Atrial Fibrillation With Combination Antithrombotic Therapy Post–Percutaneous Coronary Intervention
BACKGROUND: Up to 30% of patients with atrial fibrillation (AF) have coronary artery disease, and many undergo percutaneous coronary intervention (PCI). In the setting of acute coronary syndrome with PCI, or high-risk elective PCI, Canadian AF guidelines recommend 1-30 days of acetylsalicylic acid,...
Autores principales: | Poirier, Caylie M., Carter, Aleesa A., Kwan, Yvonne, Koo, Jessica, Westlund, Jill M., Alkass, Fadi, Leblanc, Kori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679455/ https://www.ncbi.nlm.nih.gov/pubmed/38020330 http://dx.doi.org/10.1016/j.cjco.2023.08.007 |
Ejemplares similares
-
Antithrombotic treatment in atrial fibrillation patients needing percutaneous coronary intervention
por: Huisman, M. V.
Publicado: (2021) -
Antithrombotic Strategy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
por: Kwak, Soongu, et al.
Publicado: (2019) -
Antithrombotic Therapy With Ticagrelor in Atrial Fibrillation Subjects After Percutaneous Coronary Intervention
por: Lu, Wenbin, et al.
Publicado: (2021) -
Antithrombotic Strategies in Patients with Atrial Fibrillation and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
por: De Luca, Leonardo, et al.
Publicado: (2022) -
Atrial fibrillation and percutaneous coronary intervention: Are newer antithrombotic agents better for older patients?
por: Leggio, Massimo, et al.
Publicado: (2018)